BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 28744747)

  • 1. Structural and inhibition analysis of novel sulfur-rich 2-mercaptobenzothiazole and 1,2,3-triazole ligands against Mycobacterium tuberculosis DprE1 enzyme.
    Karan S; Kashyap VK; Shafi S; Saxena AK
    J Mol Model; 2017 Aug; 23(8):241. PubMed ID: 28744747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of benzothiazoles as antimycobacterial agents: Synthesis, structure-activity relationships and binding studies with Mycobacterium tuberculosis decaprenylphosphoryl-β-D-ribose 2'-oxidase.
    Landge S; Mullick AB; Nagalapur K; Neres J; Subbulakshmi V; Murugan K; Ghosh A; Sadler C; Fellows MD; Humnabadkar V; Mahadevaswamy J; Vachaspati P; Sharma S; Kaur P; Mallya M; Rudrapatna S; Awasthy D; Sambandamurthy VK; Pojer F; Cole ST; Balganesh TS; Ugarkar BG; Balasubramanian V; Bandodkar BS; Panda M; Ramachandran V
    Bioorg Med Chem; 2015 Dec; 23(24):7694-710. PubMed ID: 26643218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluation of novel 1,2,3-triazole derivatives as anti-tubercular agents.
    Aziz Ali A; Gogoi D; Chaliha AK; Buragohain AK; Trivedi P; Saikia PJ; Gehlot PS; Kumar A; Chaturvedi V; Sarma D
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3698-3703. PubMed ID: 28712709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-activity relationship mediated molecular insights of DprE1 inhibitors: A Comprehensive Review.
    Dash S; Rathi E; Kumar A; Chawla K; Joseph A; Kini SG
    J Biomol Struct Dyn; 2024 Aug; 42(12):6472-6522. PubMed ID: 37395797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of selective DprE1 inhibitors: Design, synthesis, crystal structure and antitubercular activity of benzothiazolylpyrimidine-5-carboxamides.
    Chikhale R; Menghani S; Babu R; Bansode R; Bhargavi G; Karodia N; Rajasekharan MV; Paradkar A; Khedekar P
    Eur J Med Chem; 2015; 96():30-46. PubMed ID: 25874329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure, dynamics, and interaction of Mycobacterium tuberculosis (Mtb) DprE1 and DprE2 examined by molecular modeling, simulation, and electrostatic studies.
    Bhutani I; Loharch S; Gupta P; Madathil R; Parkesh R
    PLoS One; 2015; 10(3):e0119771. PubMed ID: 25789990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of the Development of DprE1 Inhibitors for Combating the Menace of Tuberculosis.
    Chikhale RV; Barmade MA; Murumkar PR; Yadav MR
    J Med Chem; 2018 Oct; 61(19):8563-8593. PubMed ID: 29851474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of DprE1-Mediated Benzothiazinone Resistance in Mycobacterium tuberculosis.
    Foo CS; Lechartier B; Kolly GS; Boy-Röttger S; Neres J; Rybniker J; Lupien A; Sala C; Piton J; Cole ST
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6451-6459. PubMed ID: 27527085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virtual Screening of Small Molecular Inhibitors against DprE1.
    Zhang G; Guo S; Cui H; Qi J
    Molecules; 2018 Feb; 23(3):. PubMed ID: 29495447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Veterinary Anti-Parasitic Selamectin Is a Novel Inhibitor of the
    Ezquerra-Aznárez JM; Degiacomi G; Gašparovič H; Stelitano G; Sammartino JC; Korduláková J; Governa P; Manetti F; Pasca MR; Chiarelli LR; Ramón-García S
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1.
    Neres J; Hartkoorn RC; Chiarelli LR; Gadupudi R; Pasca MR; Mori G; Venturelli A; Savina S; Makarov V; Kolly GS; Molteni E; Binda C; Dhar N; Ferrari S; Brodin P; Delorme V; Landry V; de Jesus Lopes Ribeiro AL; Farina D; Saxena P; Pojer F; Carta A; Luciani R; Porta A; Zanoni G; De Rossi E; Costi MP; Riccardi G; Cole ST
    ACS Chem Biol; 2015 Mar; 10(3):705-14. PubMed ID: 25427196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DprE1--from the discovery to the promising tuberculosis drug target.
    Mikusová K; Makarov V; Neres J
    Curr Pharm Des; 2014; 20(27):4379-403. PubMed ID: 24245764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl-β-d-Ribose Oxidase (DprE1) Inhibitors.
    Balabon O; Pitta E; Rogacki MK; Meiler E; Casanueva R; Guijarro L; Huss S; Lopez-Roman EM; Santos-Villarejo Á; Augustyns K; Ballell L; Aguirre DB; Bates RH; Cunningham F; Cacho M; Van der Veken P
    J Med Chem; 2020 May; 63(10):5367-5386. PubMed ID: 32342688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural studies of Mycobacterium tuberculosis DprE1 interacting with its inhibitors.
    Piton J; Foo CS; Cole ST
    Drug Discov Today; 2017 Mar; 22(3):526-533. PubMed ID: 27666194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DprE1 Is a Vulnerable Tuberculosis Drug Target Due to Its Cell Wall Localization.
    Brecik M; Centárová I; Mukherjee R; Kolly GS; Huszár S; Bobovská A; Kilacsková E; Mokošová V; Svetlíková Z; Šarkan M; Neres J; Korduláková J; Cole ST; Mikušová K
    ACS Chem Biol; 2015 Jul; 10(7):1631-6. PubMed ID: 25906160
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Borthwick JA; Alemparte C; Wall I; Whitehurst BC; Argyrou A; Burley G; de Dios-Anton P; Guijarro L; Monteiro MC; Ortega F; Suckling CJ; Pichel JC; Cacho M; Young RJ
    J Med Chem; 2020 Mar; 63(5):2557-2576. PubMed ID: 31922409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sulfur rich 2-mercaptobenzothiazole and 1,2,3-triazole conjugates as novel antitubercular agents.
    Mir F; Shafi S; Zaman MS; Kalia NP; Rajput VS; Mulakayala C; Mulakayala N; Khan IA; Alam MS
    Eur J Med Chem; 2014 Apr; 76():274-83. PubMed ID: 24589483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase.
    Karabanovich G; Dušek J; Savková K; Pavliš O; Pávková I; Korábečný J; Kučera T; Kočová Vlčková H; Huszár S; Konyariková Z; Konečná K; Jand'ourek O; Stolaříková J; Korduláková J; Vávrová K; Pávek P; Klimešová V; Hrabálek A; Mikušová K; Roh J
    J Med Chem; 2019 Sep; 62(17):8115-8139. PubMed ID: 31393122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and evaluation of covalent inhibitors of DprE1 as antitubercular agents.
    Liu L; Kong C; Fumagalli M; Savková K; Xu Y; Huszár S; Sammartino JC; Fan D; Chiarelli LR; Mikušová K; Sun Z; Qiao C
    Eur J Med Chem; 2020 Dec; 208():112773. PubMed ID: 32898793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of DprE1 inhibitors for tuberculosis through integrated in-silico approaches.
    Dash S; Rathi E; Kumar A; Chawla K; Kini SG
    Sci Rep; 2024 May; 14(1):11315. PubMed ID: 38760437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.